Publications by authors named "Josee Cote"

Claim this Profile
S
Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Johannes F Scheid, Kiki Cunningham-Bussel, Nancy Kim, Shiuli Agarwal, Garrett Nieddu, Josee Cote

Immunohorizons· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.
Jonathan A Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey, Tami Crumley, Josee Cote

EBioMedicine· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Petr Vachal, Joseph L Duffy, Louis-Charles Campeau, Rupesh P Amin, Kaushik Mitra, Josee Cote

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
Rajesh Krishna, Ferdous Gheyas, Christy Corr, Josee Cote, Yang Liu

J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
Rajesh Krishna, Ferdous Gheyas, Yang Liu, Josee Cote, Omar Laterza

J Clin Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Brett Lauring, Xiujiang Susie Li, Yang Liu, Christy Corr, Nicole Lazarus, Josee Cote

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.
Matt S Anderson, Josee Cote, Yang Liu, Daria Stypinski, Patrice Auger

J Clin Pharmacol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Perceptions regarding dialysis cessation and life support treatments in patients from Quebec undergoing hospital hemodialysis: age comparison].
Judith Gagnon, Jocelyne Saint-Arnaud, Marc Bourdeau, Josée Côté, Claire Chapados

Can J Aging· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Brett Lauring, Andrew K P Taggart, James R Tata, Richard Dunbar, Luzelena Caro, Josee Cote

Sci Transl Med· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Rajesh Krishna, Daria Stypinski, Melissa Ali, Amit Garg, Josee Cote

Br J Clin Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.
P Douglas Boatman, Brett Lauring, Thomas O Schrader, Michelle Kasem, Benjamin R Johnson, Josee Cote

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Brett Lauring, Victor Dishy, Wen-Lin Luo, Omar Laterza, Jaclyn Patterson, Josee Cote

J Clin Pharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Rajesh Krishna, Amit Garg, Deborah Panebianco, Josee Cote, Arthur J Bergman

Br J Clin Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of sitagliptin on the pharmacokinetics of simvastatin.
Arthur J Bergman, Josee Cote, Andrea Maes, Jamie J Zhao, Brad A Roadcap

J Clin Pharmacol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Rajesh Krishna, Arthur J Bergman, Bo Jin, Amit Garg, Brad Roadcap, Josee Cote

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Carol Addy, Paul Rothenberg, Susie Li, Anup Majumdar, Nancy Agrawal, Josee Cote

J Clin Pharmacol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Carol Addy, Susie Li, Nancy Agrawal, Julie Stone, Anup Majumdar, Josee Cote

J Clin Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects.
Koen Van Laere, Michel Koole, Sandra M Sanabria Bohorquez, Karolien Goffin, Ilonka Guenther, Josee Cote

J Nucl Med· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Carol Addy, Hamish Wright, Koen Van Laere, Ira Gantz, Ngozi Erondu, Josee Cote

Cell Metab· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Rajesh Krishna, Matt S Anderson, Arthur J Bergman, Bo Jin, Marissa Fallon, Josee Cote

Lancet· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Arthur J Bergman, Josee Cote, Bingming Yi, Thomas Marbury, Suzanne K Swan

Diabetes Care· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
H Donald Burns, Koen Van Laere, Sandra Sanabria-Bohórquez, Terence G Hamill, Guy Bormans, Josee Cote

Proc Natl Acad Sci U S A· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
Jules I Schwartz, Nancy G B Agrawal, Alan H Hartford, Josee Cote, Thomas L Hunt

J Clin Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Rajesh Krishna, Arthur Bergman, Patrick Larson, Josee Cote, Kenneth Lasseter

J Clin Pharmacol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Ngozi Erondu, Ira Gantz, Bret Musser, Shailaja Suryawanshi, Madhuja Mallick, Josee Cote

Cell Metab· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis